(Total Views: 534)
Posted On: 03/08/2018 10:19:18 AM
Post# of 30066
Couple of real interesting things in the PR.
The EU part of the trial didn't stop until 2016. Wonder if there were some preliminary results with a few of the participants.
The company is planning a Phase 3 not a Phase 2 for the treatment of PD-LID. That will peak some investors' interest. Go back to the market comps and see what a company is worth heading into Phase 3
The EU part of the trial didn't stop until 2016. Wonder if there were some preliminary results with a few of the participants.
The company is planning a Phase 3 not a Phase 2 for the treatment of PD-LID. That will peak some investors' interest. Go back to the market comps and see what a company is worth heading into Phase 3
Quote:
An IND for Eltoprazine was opened with the neurology division of the US FDA in May 2015 that allowed the Company to initiate a multi-center, randomized, placebo-controlled crossover design Phase 2b trial of Eltoprazine in the treatment of PD-LID in the United States and Europe that was put on recruitment hold in September 2015. The European portion of the trial was closed in 2016. The Company is currently preparing to redesign its Phase 2b PD-LID trial into a Phase 3-enabling parallel design clinical trial as a result of the recent approval of Gocovri from Adamas Pharmaceuticals for the treatment of PD-LID. Elto Pharma is in the process of recruiting seasoned management to lead Elto Pharma going forward.
(10)
(0)
